These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 21220609)

  • 1. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.
    Marcucci G; Haferlach T; Döhner H
    J Clin Oncol; 2011 Feb; 29(5):475-86. PubMed ID: 21220609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in AML in relation to (ab)normal karyotype.
    Stone RM
    Best Pract Res Clin Haematol; 2009 Dec; 22(4):523-8. PubMed ID: 19959103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic factors of acute myeloid leukemia].
    Inokuchi K
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():389-93. PubMed ID: 23133988
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
    Martelli MP; Sportoletti P; Tiacci E; Martelli MF; Falini B
    Blood Rev; 2013 Jan; 27(1):13-22. PubMed ID: 23261068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of specific microRNA and their targets in acute myeloid leukemia.
    Cammarata G; Augugliaro L; Salemi D; Agueli C; La Rosa M; Dagnino L; Civiletto G; Messana F; Marfia A; Bica MG; Cascio L; Floridia PM; Mineo AM; Russo M; Fabbiano F; Santoro A
    Am J Hematol; 2010 May; 85(5):331-9. PubMed ID: 20425795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.
    Ishikawa Y; Kiyoi H; Tsujimura A; Miyawaki S; Miyazaki Y; Kuriyama K; Tomonaga M; Naoe T
    Eur J Haematol; 2009 Aug; 83(2):90-8. PubMed ID: 19309322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of acute myeloid leukemia.
    Döhner K; Döhner H
    Haematologica; 2008 Jul; 93(7):976-82. PubMed ID: 18591623
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically useful prognostic factors in acute myeloid leukemia.
    Ferrara F; Palmieri S; Leoni F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):181-93. PubMed ID: 17996460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia.
    Baldus CD; Bullinger L
    Semin Oncol; 2008 Aug; 35(4):356-64. PubMed ID: 18692686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplex high-throughput gene mutation analysis in acute myeloid leukemia.
    Dunlap J; Beadling C; Warrick A; Neff T; Fleming WH; Loriaux M; Heinrich MC; Kovacsovics T; Kelemen K; Leeborg N; Gatter K; Braziel RM; Press R; Corless CL; Fan G
    Hum Pathol; 2012 Dec; 43(12):2167-76. PubMed ID: 22658276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [THE CLINICAL SIGNIFICANCE OF GENETIC MUTATIONS IN ACUTE MYELOID LEUKEMIA].
    Goryainova NV
    Lik Sprava; 2014 Dec; (12):10-8. PubMed ID: 26638462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and prognosis in acute myeloid leukemia--the art of distinction.
    Löwenberg B
    N Engl J Med; 2008 May; 358(18):1960-2. PubMed ID: 18450608
    [No Abstract]   [Full Text] [Related]  

  • 14. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
    Sritana N; Auewarakul CU
    Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comprehensive analysis of gene abnormalities in acute myeloid leukemia according to the WHO classification].
    Ishikawa Y
    Rinsho Ketsueki; 2009 Aug; 50(8):597-603. PubMed ID: 19915373
    [No Abstract]   [Full Text] [Related]  

  • 16. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia.
    Wakita S; Yamaguchi H; Miyake K; Mitamura Y; Kosaka F; Dan K; Inokuchi K
    Leukemia; 2011 Sep; 25(9):1423-32. PubMed ID: 21606963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling in acute myeloid leukaemia (AML).
    Bacher U; Kohlmann A; Haferlach C; Haferlach T
    Best Pract Res Clin Haematol; 2009 Jun; 22(2):169-80. PubMed ID: 19698926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse.
    Wang ES; Sait SN; Gold D; Mashtare T; Starostik P; Ford LA; Wetzler M; Nowak NJ; Deeb G
    Cancer Genet Cytogenet; 2010 Oct; 202(2):101-7. PubMed ID: 20875872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.